GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (CHIX:SOBIs) » Definitions » Shiller PE Ratio

Swedish Orphan Biovitrum AB (CHIX:SOBIS) Shiller PE Ratio : 37.28 (As of Jun. 23, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Swedish Orphan Biovitrum AB Shiller PE Ratio?

As of today (2024-06-23), Swedish Orphan Biovitrum AB's current share price is kr279.60. Swedish Orphan Biovitrum AB's E10 for the quarter that ended in Mar. 2024 was kr7.50. Swedish Orphan Biovitrum AB's Shiller PE Ratio for today is 37.28.

The historical rank and industry rank for Swedish Orphan Biovitrum AB's Shiller PE Ratio or its related term are showing as below:

CHIX:SOBIs' s Shiller PE Ratio Range Over the Past 10 Years
Min: 28.96   Med: 50.05   Max: 544.45
Current: 36.53

During the past years, Swedish Orphan Biovitrum AB's highest Shiller PE Ratio was 544.45. The lowest was 28.96. And the median was 50.05.

CHIX:SOBIs's Shiller PE Ratio is ranked worse than
69.29% of 534 companies
in the Drug Manufacturers industry
Industry Median: 24.175 vs CHIX:SOBIs: 36.53

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Swedish Orphan Biovitrum AB's adjusted earnings per share data for the three months ended in Mar. 2024 was kr2.330. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is kr7.50 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Swedish Orphan Biovitrum AB Shiller PE Ratio Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Shiller PE Ratio Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 59.36 44.07 38.36 33.79 37.27

Swedish Orphan Biovitrum AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.62 30.12 33.00 37.27 35.31

Competitive Comparison of Swedish Orphan Biovitrum AB's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Shiller PE Ratio falls into.



Swedish Orphan Biovitrum AB Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Swedish Orphan Biovitrum AB's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=279.60/7.5
=37.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Swedish Orphan Biovitrum AB's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Swedish Orphan Biovitrum AB's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.33/132.2054*132.2054
=2.330

Current CPI (Mar. 2024) = 132.2054.

Swedish Orphan Biovitrum AB Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 0.096 100.432 0.126
201409 0.191 100.161 0.252
201412 -0.067 100.225 -0.088
201503 0.267 99.950 0.353
201506 -0.010 99.995 -0.013
201509 0.019 100.228 0.025
201512 -0.048 100.276 -0.063
201603 1.070 100.751 1.404
201606 1.098 101.019 1.437
201609 0.478 101.138 0.625
201612 0.267 102.022 0.346
201703 0.716 102.022 0.928
201706 0.936 102.752 1.204
201709 1.146 103.279 1.467
201712 1.261 103.793 1.606
201803 1.815 103.962 2.308
201806 2.417 104.875 3.047
201809 2.197 105.679 2.748
201812 2.092 105.912 2.611
201903 2.980 105.886 3.721
201906 1.614 106.742 1.999
201909 1.748 107.214 2.155
201912 4.394 107.766 5.390
202003 3.802 106.563 4.717
202006 0.907 107.498 1.115
202009 0.888 107.635 1.091
202012 4.805 108.296 5.866
202103 2.226 108.360 2.716
202106 0.860 108.928 1.044
202109 1.519 110.338 1.820
202112 3.993 112.486 4.693
202203 1.748 114.825 2.013
202206 0.821 118.384 0.917
202209 1.420 122.296 1.535
202212 4.450 126.365 4.656
202303 3.400 127.042 3.538
202306 0.707 129.407 0.722
202309 0.300 130.224 0.305
202312 3.000 131.912 3.007
202403 2.330 132.205 2.330

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Swedish Orphan Biovitrum AB  (CHIX:SOBIs) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Swedish Orphan Biovitrum AB Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB (CHIX:SOBIS) Business Description

Traded in Other Exchanges
Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB (CHIX:SOBIS) Headlines

No Headlines